Lomeli LD, Kodali AM, Tsushima Y, Mehta AE, Pantalone KM
People with liver disease Tirzepatide is metabolized through proteolytic cleavage rather than hepatic metabolism, which means liver disease does not significantly alter tirzepatide drug levels
[3] Less common but clinically important adverse events include acute pancreatitis, gallbladder disease, acute kidney injury secondary to dehydration from GI adverse events, and hypoglycemia when tirzepatide is co-administered with insulin or insulin secretagogues such as sulfonylureas
Analysis of surgical interventions To assess whether observed differences in cataract diagnosis translated into measurable healthcare utilization, we examined cataract surgery rates across treatment groups using CPT procedure codes (Supplementary Fig
Constipation hits approximately 24% of Wegovy users and 20-25% of Zepbound users